Search Results - "MACHIELS, J. J"

Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Machiels, J-P, René Leemans, C, Golusinski, W, Grau, C, Licitra, L, Gregoire, V

Get full text

Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up by Bossi, P., Chan, A.T., Licitra, L., Trama, A., Orlandi, E., Hui, E.P., Halámková, J., Mattheis, S., Baujat, B., Hardillo, J., Smeele, L., van Herpen, C., Castro, A., Machiels, J.-P.

“…•This ESMO-EURACAN Clinical Practice Guideline provides key recommendations for managing nasopharyngeal cancer (NPC).•It covers screening, clinical and…”
Get full text

ESMO–EURACAN Clinical Practice Guideline update for nasopharyngeal carcinoma: adjuvant therapy and first-line treatment of recurrent/metastatic disease by Bossi, P., Chan, A.T., Even, C., Machiels, J.-P.

“…•This special article provides updated treatment recommendations for nasopharyngeal carcinoma.•In high-risk locoregionally advanced NPC, adding metronomic or…”
Get full text

Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery by Forget, P., Bentin, C., Machiels, J.-P., Berliere, M., Coulie, P.G., De Kock, M.

“…An association between the use of non-steroidal anti-inflammatory drugs (NSAIDs) and better outcome after mastectomy and lung surgery for cancer has been…”
Get full text

Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study by Psyrri, A., Fayette, J., Harrington, K., Gillison, M., Ahn, M.-J., Takahashi, S., Weiss, J., Machiels, J.-P., Baxi, S., Vasilyev, A., Karpenko, A., Dvorkin, M., Hsieh, C.-Y., Thungappa, S.C., Segura, P.P., Vynnychenko, I., Haddad, R., Kasper, S., Mauz, P.-S., Baker, V., He, P., Evans, B., Wildsmith, S., Olsson, R.F., Yovine, A., Kurland, J.F., Morsli, N., Seiwert, T.Y.

“…Patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) have a poor prognosis. The phase III KESTREL study evaluated the…”
Get full text

Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer by Cohen, E.E.W., Licitra, L.F., Burtness, B., Fayette, J., Gauler, T., Clement, P.M., Grau, J.J., del Campo, J.M., Mailliez, A., Haddad, R.I., Vermorken, J.B., Tahara, M., Guigay, J., Geoffrois, L., Merlano, M.C., Dupuis, N., Krämer, N., Cong, X.J., Gibson, N., Solca, F., Ehrnrooth, E., Machiels, J.-P.H.

“…In the phase III LUX-Head & Neck 1 (LUX-H&N1) trial, second-line afatinib significantly improved progression-free survival (PFS) versus methotrexate in…”
Get full text

Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach by Galot, R., Le Tourneau, C., Guigay, J., Licitra, L., Tinhofer, I., Kong, A., Caballero, C., Fortpied, C., Bogaerts, J., Govaerts, A.-S., Staelens, D., Raveloarivahy, T., Rodegher, L., Laes, J.-F., Saada-Bouzid, E., Machiels, J.-P.

“…The molecular landscape of squamous cell carcinoma of the head and the neck (SCCHN) has been characterized and actionable or targetable genomic alterations…”
Get full text

Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma by Nutting, C.M., van Herpen, C.M.L., Miah, A.B., Bhide, S.A., Machiels, J.-P., Buter, J., Kelly, C., de Raucourt, D., Harrington, K.J.

“…Background: Treatment options for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) are limited with response rates to cytotoxic…”
Get full text

Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers by Seront, E., Rottey, S., Sautois, B., Kerger, J., D'Hondt, L.A., Verschaeve, V., Canon, J.-L., Dopchie, C., Vandenbulcke, J.M., Whenham, N., Goeminne, J.C., Clausse, M., Verhoeven, D., Glorieux, P., Branders, S., Dupont, P., Schoonjans, J., Feron, O., Machiels, J.-P.

“…This phase II study assessed the safety and efficacy of everolimus, an oral mammalian target of rapamycin inhibitor in advanced transitional carcinoma cell…”
Get full text

Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02) by Schmitz, S., Kaminsky-Forrett, M.-C., Henry, S., Zanetta, S., Geoffrois, L., Bompas, E., Moxhon, A., Mignion, L., Guigay, J., Knoops, L., Hamoir, M., Machiels, J.-P.

“…Preclinical studies suggest that insulin-like growth factor-1 receptor (IGF-1R) blockage could be a promising therapeutic target in squamous cell carcinoma of…”
Get full text

Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence by Harrington, K.J., Cohen, E.E.W., Soulières, D., Dinis, J., Licitra, L., Ahn, M.-J., Soria, A., Machiels, J.-P., Mach, N., Mehra, R., Burtness, B., Swaby, R.F., Lin, J., Ge, J., Lerman, N., Tourneau, C. Le

“…•OS was numerically longer with pembrolizumab in all subgroups.•PFS was similar between treatment arms in all subgroups.•More patients receiving pembrolizumab…”
Get full text

Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN) by Machiels, J.-P., Bossi, P., Menis, J., Lia, M., Fortpied, C., Liu, Y., Lhommel, R., Lemort, M., Schmitz, S., Canevari, S., De Cecco, L., Guzzo, M., Bianchi, R., Quattrone, P., Crippa, F., Duprez, T., Lalami, Y., Quiriny, M., de Saint Aubain, N., Clement, P.M., Coropciuc, R., Hauben, E., Licitra, L.F.

“…To investigate the activity and safety of afatinib in the preoperative treatment of squamous cell carcinoma of the head and neck (SCCHN). This study was an…”
Get full text

Reprint of “Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up” by Machiels, J.-P., René Leemans, C., Golusinski, W., Grau, C., Licitra, L., Gregoire, V.

“…•This EHNS-ESMO-ESTRO Clinical Practice Guideline provides key recommendations for managing SCCHN.•It covers clinical and pathological diagnosis, staging and…”
Get full text

Cancer and renal insufficiency results of the BIRMA study by Janus, N, Launay-vacher, V, Byloos, E, Machiels, J-P, Duck, L, Kerger, J, Wynendaele, W, Canon, J-L, Lybaert, W, Nortier, J, Deray, G, Wildiers, H

“…Background: Half of anticancer drugs are predominantly excreted in urine. Dosage adjustment in renal insufficiency (RI) is, therefore, a crucial issue…”
Get full text

PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation by Seront, E, Pinto, A, Bouzin, C, Bertrand, L, Machiels, J-P, Feron, O

“…Background: Preclinical studies have shown that PTEN loss enhances sensitivity to mammalian target of Rapamycin (mTOR) inhibitors because of facilitated PI3K…”
Get full text

A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors by Vermorken, J.B., Rottey, S., Ehrnrooth, E., Pelling, K., Lahogue, A., Wind, S., Machiels, J.-P.

“…In this phase Ib, dose-escalation study, the oral irreversible ErbB family blocker afatinib (BIBW 2992) was combined with cisplatin (Cadila Healthcare Ltd,…”
Get full text

Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck by Schmitz, S., Hamoir, M., Reychler, H., Magremanne, M., Weynand, B., Lhommel, R., Hanin, F.-X., Duprez, T., Michoux, N., Rommel, D., Lonneux, M., Cappoen, N., Gillain, A., Machiels, J.-P.

“…To investigate the safety and activity of cetuximab in the pre-operative treatment of squamous cell carcinoma of the head and neck (SCCHN). Cetuximab was…”
Get full text

Salivary gland cancer: ESMO–European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up by van Herpen, C., Vander Poorten, V., Skalova, A., Terhaard, C., Maroldi, R., van Engen, A., Baujat, B., Locati, L.D., Jensen, A.D., Smeele, L., Hardillo, J., Martineau, V. Costes, Trama, A., Kinloch, E., Even, C., Machiels, J.-P.

“…•This ESMO–EURACAN Clinical Practice Guideline provides key recommendations for managing salivary gland cancer.•The guideline covers clinical and pathological…”
Get full text

A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck by Machiels, J.-P., Specenier, P., Krauß, J., Dietz, A., Kaminsky, M.-C., Lalami, Y., Henke, M., Keilholz, U., Knecht, R., Skartved, N. J., Horak, I. D., Pamperin, P., Braun, S., Gauler, T. C.

“…Purpose The purpose of the trial was to assess the efficacy and tolerability of Sym004, a novel 1:1 mixture of two chimeric monoclonal antibodies (992 and…”
Get full text

Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study by Guigay, J., Fayette, J., Dillies, A.F., Sire, C., Kerger, J.N., Tennevet, I., Machiels, J.P., Zanetta, S., Pointreau, Y., Bozec Le Moal, L., Henry, S., Schilf, A., Bourhis, J.

“…Cetuximab in combination with platinum and 5-fluorouracil is the standard of care in the first-line treatment of patients with recurrent/metastatic head and…”
Get full text